TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma
TuHURA Biosciences reported initial data from the first three patients in its open-label Phase 1b/2a study of IFx-2.0 plus Keytruda in first-line metastatic Merkel Cell Carcinoma. All three patients achieved partial responses per RECIST v1.1, with every response ongoing at the protocol-specified six-month assessment, and CT/ultrasound-guided administration was shown to be safe and feasible in deep-seated bulky tumors.
Key figures
- Drug Name
- IFx-2.0
- Phase Of Trial
- Phase 1b/2a
- Ifx dose
- 0.1 mg weekly for 3 weeks into a single deep-seated tumor
- Responses
- 3/3 partial responses (RECIST v1.1), ongoing at 6-month assessment
- Indication
- first-line metastatic Merkel Cell Carcinoma
- Patients reported
- 3
- Planned enrollment
- 9
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.